Turnover: ()
Country: United States
American biotech company best known for developing a vaccine against Covid
News
Moderna successfully improves its flu vaccine candidate 14/09/2023
- Moderna sold $18 billion of Covid vaccines by 2022
- Flu vaccination market forecast at $9 billion in 2028, compared with $5.8 billion in 2020 and $2.8 billion in 2010
- 15 new vaccines to be launched by Moderna in five years
- Moderna plans to target only respiratory viruses by 2025, with vaccines for other diseases arriving in 2026-2028
- Moderna is testing a melanoma vaccine in phase 3 with Merck, and plans to move into phase 3 on lung cancer this year
- Moderna has invested $1.8 billion in German biotech Immatics for a partnership in cancer vaccines.
Moderna dreams of championing vaccines 14/09/2023
- Moderna plans to launch up to 15 new products within five years
- Moderna plans to invest $25 billion between 2024 and 2028.
- Moderna's Covid sales are $19.3 billion, with $8.4 billion in profits.
- Moderna's workforce is expected to grow from 4,000 to 6,000 in one year.
- Moderna's Covid vaccine sales are expected to decline to between $6 and $8 billion by 2023.
- The bronchiolitis vaccine market could reach $10-12 billion in sales.
- Moderna plans to penetrate the flu market, valued at $6 billion.
- Moderna plans to generate between $8 and $15 billion in annual revenues from respiratory vaccines by 2027.
Moderna still aims for a plant in France 13/11/2022
- Moderna calls on the French government for a "long-term commitment" to purchase its respiratory vaccines
- Investment of around one billion euros for a plant and research center dedicated to RNA vaccines
- The future site, which will serve the domestic market as early as 2025